Atara Biotherapeutics faces a precarious outlook as its reliance on non-recurring milestone payments has resulted in a severe revenue contraction from $98.1 million in 2025Q1 to $516.0K in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.32-1.6% vs -$0.32 | $630,000+14.5% vs $550,000 |
Q2 2026 May 14, 2026 | -$0.29+12.0% vs -$0.33 | $516,000-82.2% vs $3M |
Q2 2026 May 12, 2026 | -$0.29+12.0% vs -$0.33 | $516,000-82.2% vs $3M |
Q2 2026 Mar 16, 2026 | -$0.25-177.8% vs -$0.09 | $2M-51.2% vs $3M |
Atara Biotherapeutics, Inc. (NASDAQ: ATRA - Get Free Report) shares passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $9.23 and traded as high as $9.91. Atara Biotherapeutics shares last traded at $9.18, with a volume of 19,493 shares trading hands. Wall Street Analyst Weigh
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) resubmission for tabelecleucel,.
Atara Biotherapeutics (NASDAQ: ATRA - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability. Profitability This table compares Atara Biotherapeutics and
[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platf
Benchmark ATRA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Atara Biotherapeutics, Inc. (ATRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.87 | $70.91M | -7.09 | -6.33% | -269.42% | — | — | |
| $1.84 | $214.47M | -1.83 | -51.24% | -2619.64% | -73.92% | — | |
| $1.58 | $200.96M | -2.53 | 14.85% | -123.03% | — | — | |
| $1.30 | $211.97M | -1.28 | — | — | -106.78% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — |
Atara Biotherapeutics, Inc. (ATRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Atara Biotherapeutics, Inc. (ATRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 26, 2026·SEC
Jun 12, 2026·SEC
Get notified when ATRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Atara Biotherapeutics, Inc. (ATRA) stock FAQ — growth, dividends, profitability & financials explained
Atara Biotherapeutics, Inc. (ATRA) reported $6.2M in revenue over the trailing twelve months. Revenue was $120.8M in fiscal year 2025.
Atara Biotherapeutics, Inc. (ATRA) revenue fell by 96.7% over the trailing twelve months, compared with the twelve months before.
No. Atara Biotherapeutics, Inc. (ATRA) reported a net loss of $16.7M over the trailing twelve months.
Atara Biotherapeutics, Inc. (ATRA) had negative free cash flow of $21.9M over the trailing twelve months.
